Intellectual property rights, especially patents, frequently form the foundation of value in a life sciences company. If conducted with eventual commercial success in mind, a due diligence review of an IP portfolio can enable an investor to assess more accurately the present and future value of the technology and IP associated with an investment. Often times however, little thought is given as to how to leverage the harvested intelligence in the commercialization process of the acquired technology after the deal. This panel discussed:
- The IP due diligence process – what to expect and preparing for the unexpected
- Working the IP – identifying and valuing know-how to execute the IP
- The technology factor – working with R & D during and after the diligence process
Presenters included:
- Jana Diesner, Carnegie Mellon University
- James Ewing, Senior Counsel, Biotechnology & Pharmaceutical Practice, Foley
- John Gutkoski, Partner, IP Litigation Practice, Foley
- Antoinette Konski, Partner, Biotechnology & Pharmaceutical Practice, Foley
- Dr. Roxanne Spencer, Ph.D., Patent Manager, Antisoma, Inc.
- Christopher Verni, Patent Counsel, Genzyme Corporation
Related Insights
13 May 2025
IP Litigation Current
Alice Patent Eligibility Analysis Divergance before USPTO and District Court: Federal Circuit Clarifies Limits on Relying on USPTO Findings in § 101 Eligibility Disputes
13 May 2025
Energy Current
High-Level Overview of certain Provisions Impacting Renewable Energy Incentives in “The One, Big, Beautiful Bill” Draft Legislation
13 May 2025
Foley Viewpoints
DOL Alters Enforcement Position on Independent Contractors: What Does It Mean Manufacturers and Franchisors?
On May 1, 2025, the Wage and Hour Division of the U.S. Department of Labor issued a Field Assistance Bulletin stepping back from a restrictive independent contractor rule issued under the Biden administration—a move manufacturers and franchisors should welcome to the extent they depend on business models including independent contractors.